|
1
|
Petruzziello A, Marigliano S, Loquercio G,
Cozzolino A and Cacciaputi C: Global epidemiology of hepatitis C
virus infection: An up-date of the distribution and circulation of
hepatitis C virus genotypes. World J Gastroenterol. 22:7824–7840.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Schamberg NJ and Lake-Bakaar GV: Hepatitis
C virus-related mixed cryoglobulinemia: Pathogenesis, Clinica
manifestations, and new therapies. Gastroenterol Hepatol (NY).
3:695–703. 2007.PubMed/NCBI
|
|
3
|
Timofte D, Dragos D, Balcangiu-Stroescu
AE, Tanasescu MD, Gabriela Balan D, Avino A, Tulin A, Stiru O and
Ionescu D: Infection with hepatitis C virus in hemodialysis
patients: An overview of the diagnosis and prevention rules within
a hemodialysis center (Review). Exp Ther Med. 20:109–116.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Balcangiu-Stroescu AE, Tanasescu MD,
Diaconescu AC, Raducu L, Constantin AM, Balan DG, Tarmure V and
Ionescu D: Cardiovascular comorbidities, inflammation and serum
albumin levels in a group of hemodialysis patients. Rev Chim
Buchar. 69:926–929. 2018.
|
|
5
|
Dustin LB: Innate and adaptive immune
responses in chronic HCV infection. Curr Drug Targets. 18:826–843.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Suceveanu AI, Stoian AP, Mazilu L, Voinea
F, Hainarosie R, Diaconu CC, Pituru S, Nitipir C, Badiu DC, Ceausu
I and Suceveanu AP: Interferon-free therapy is not a trigger for
hepatocellular carcinoma in patients with chronic infection with
hepatitis C virus. Farmacia. 66:904–908. 2018.
|
|
7
|
Marinescu I, Schenker RA, Stovicek PO,
Marinescu D, Ciobanu CF, Papacocea SI, Manea MC, Papacocea RI,
Manea M, Chirita R and Ciobanu AM: Biochemical factors involved in
the unfavorable evolution of prostate cancer. Rev Chim.
70:3343–3347. 2019.
|
|
8
|
Papacocea MT, Badarau IA, Radoi M and
Papacocea IR: The predictive role of biochemical plasma factors in
patients with severe traumatic brain injuries. Rev Chim Buchar.
70:1754–1757. 2019.
|
|
9
|
Sheridan DA, Aithal G, Alazawi W, Allison
M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S, Newsome PN,
et al: Care standards for non-alcoholic fatty liver disease in the
United Kingdom 2016: A cross-sectional survey. Frontline
Gastroenterol. 8:252–259. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sagnelli E, Santantonio T, Coppola N,
Fasano M, Pisaturo M and Sagnelli C: Acute hepatitis C: Clinical
and laboratory diagnosis, course of the disease, treatment.
Infection. 42:601–610. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Fierbinteanu-Braticevici C, Papacocea R,
Tribus L and Baicus C: Role of 13C methacetin breath test for non
invasive staging of liver fibrosis in patients with chronic
hepatitis C. Indian J Med Res. 140:123–129. 2014.PubMed/NCBI
|
|
12
|
Christiansen M, Høgdall CK, Andersen JR
and Nørgaard-Pedersen B: Alpha-fetoprotein in plasma and serum of
healthy adults: Preanalytical, analytical and biological sources of
variation and construction of age-dependent reference intervals.
Scand J Clin Lab Invest. 61:205–215. 2001.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Spătaru RI, Enculescu A and Popoiu MC:
Gruber-Frantz tumor: A very rare pathological condition in
children. Rom J Morphol Embryol. 55:1497–1501. 2014.PubMed/NCBI
|
|
14
|
Chen CH, Lin ST, Kuo CL and Nien CK:
Clinical significance of elevated alpha-fetoprotein (AFP) in
chronic hepatitis C without hepatocellular carcinoma.
Hepatogastroenterology. 55:1423–1427. 2008.PubMed/NCBI
|
|
15
|
Timofte D, Mandita A, Balcangiu-Stroescu
AE, Balan D, Raducu L, Tanasescu MD, Diaconescu A, Dragos D,
Cosconel CI, Stoicescu SM and Ionescu D: Hyperuricemia and
cardiovascular diseases-clinical and paraclinical correlations. Rev
Chim. 70:1045–1046. 2019.
|
|
16
|
Timofte D, Dragoș D, Balcangiu-Stroescu
AE, Tănăsescu MD, Gabriela Bălan D, Răducu L, Tulin A, Stiru O and
Ionescu D: Abdominal aortic calcification in predialysis patients:
Contribution of traditional and uremia-related risk factors. Exp
Ther Med. 20:97–102. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Timofte D, Ionescu D, Medrihan L, Mandita
A, Rasina A and Damian L: Vascular calcification and bone disease
in hemodialysis patient, assessment, association and risk factors.
Nephrol Dial Transplant. 22:325–326. 2007.
|
|
18
|
Gaman MA, Dobrica EC, Pascu EG, Cozma MA,
Epingeac ME, Gaman AM, Pantea Stoian AM, Bratu OG and Diaconu CC:
Cardio metabolic risk factors for atrial fibrillation in type 2
diabetes mellitus: Focus on hypertension, metabolic syndrome and
obesity. J Mind Med Sci. 6:157–161. 2019.
|
|
19
|
Emokpae MA, Adejumol BG, Abdu A and Sadiq
NM: Serum alpha-fetoprotein level is higher in hepatitis C than
hepatitis B infected chronic liver disease patients. Niger Med J.
54:426–429. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tai WC, Hu TH, Wang JH, Hung CH, Lu SN,
Changchien CS and Lee CM: Clinical implications of
alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc.
108:210–218. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Di Bisceglie AM, Sterling RK, Chung RT,
Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT,
Lindsay KL, Lok AS, et al: Serum alpha-fetoprotein levels in
patients with advanced hepatitis C: Results from the HALT-C trial.
J Hepatol. 43:434–441. 2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Abdoul H, Mallet V, Pol S and Fontanet A:
Serum alpha-fetoprotein predicts treatment outcome in chronic
hepatitis C patients regardless of HCV genotype. PLoS One.
3(e2391)2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ozkok A and Yildiz A: Hepatitis C virus
associated glomerulopathies. World J Gastroenterol. 20:7544–7554.
2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Morra E: Cryoglobulinemia. Hematology Am
Soc Hematol Educ Program: 368-372, 2005.
|
|
25
|
Gamil M, Alboraie M, El-Sayed M,
Elsharkawy A, Asemn N, Elbaz T, Mokey M, Abbas B, Mehrez M and
Esmat G: Novel scores combining AFP with non-invasive markers for
prediction of liver fibrosis in chronic hepatitis C patients. J Med
Virol. 90:1080–1086. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Fierbinteanu-Braticevici C, Baicus C,
Tribus L and Papacocea R: Predictive factors for nonalcoholic
steatohepatitis (NASH) in patients with nonalcoholic fatty liver
disease (NAFLD). J Gastrointestin Liv Dis. 20:153–159.
2011.PubMed/NCBI
|
|
27
|
Martinot-Peignoux M, Stern C, Maylin S,
Ripault MP, Boyer N, Leclere L, Castelnau C, Giuily N, El Ray A,
Cardoso AC, et al: Twelve weeks posttreatment follow-up is as
relevant as 24 weeks to determine the sustained virologic response
in patients with hepatitis C virus receiving pegylated interferon
and ribavirin. Hepatology. 51:1122–1126. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lucero C and Brown RS Jr: Noninvasive
measures of liver fibrosis and severity of liver disease.
Gastroenterol Hepatol (NY). 12:33–40. 2016.PubMed/NCBI
|
|
29
|
He Y, Lu H and Zhang L: Serum AFP levels
in patients suffering from 47 different types of cancers and
noncancer diseases. Prog Mol Biol Transl Sci. 162:199–212.
2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yoo T, Lee KW, Yi NJ, Choi YR, Kim H, Suh
SW, Jeong JH, Lee JM and Suh KS: Peri-transplant change in AFP
level: A useful predictor of hepatocellular carcinoma recurrence
following liver transplantation. J Korean Med Sci. 31:1049–1054.
2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ahn DG, Kim HJ, Kang H, Lee HW, Bae SH,
Lee JH, Paik YH and Lee JS: Feasibility of α-fetoprotein as a
diagnostic tool for hepatocellular carcinoma in Korea. Korean J
Intern Med. 31:46–53. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen TM, Huang PT, Tsai MH, Lin LF, Liu
CC, Ho KS, Siauw CP, Chao PL and Tung JN: Predictors of
alpha-fetoprotein elevation in patients with chronic hepatitis C,
but not hepatocellular carcinoma, and its normalization after
pegylated interferon alfa 2a-ribavirin combination therapy. J
Gastroenterol Hepatol. 22:669–675. 2007.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yang JG, He XF, Huang B, Zhang HA and He
YK: Rule of changes in serum GGT levels and GGT/ALT and AST/ALT
ratios in primary hepatic carcinoma patients with different AFP
levels. Cancer Biomark. 21:743–746. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Landau DA, Saadoun D, Halfon P,
Martinot-Peignoux M, Marcellin P, Fois E and Cacoub P: Relapse of
hepatitis C virus-associated mixed cryoglobulinemia vasculitis in
patients with sustained viral response. Arthritis Rheum.
58:604–611. 2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Santoriello D, Pullela NK, Uday KA, Dhupar
S, Radhakrishnan J, D'Agati VD and Markowitz GS: Persistent
hepatitis C Virus-associated cryoglobulinemic glomerulonephritis in
patients successfully treated with direct-acting antiviral therapy.
Kidney Int Rep. 3:985–990. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Pan JJ, Bao F, Du E, Skillin C, Frenette
CT, Waalen J, Alaparthi L, Goodman ZD and Pockros PJ: Morphometry
confirms fibrosis regression from sustained virologic response to
direct-acting antivirals for hepatitis C. Hepatol Commun.
2:1320–1330. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ilie M, Rusu M, Rosianu C, Neagu TP,
Motofei IG, Bratu OG, Socea B, Stanescu AMA, Gherghiceanu F, Pantea
Stoian A, et al: Ultrasound-guided biopsy in focal liver lesions.
Arch Balk Med Union. 53:364–368. 2018.
|
|
38
|
Wang JH, Changchien CS, Hung CH, Tung WC,
Kee KM, Chen CH, Hu TH, Lee CM and Lu SN: Liver stiffness decrease
after effective antiviral therapy in patients with chronic
hepatitis C: Longitudinal study using FibroScan. J Gastroenterol
Hepatol. 25:964–969. 2010.PubMed/NCBI View Article : Google Scholar
|
